Cargando…
Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy
BACKGROUND: The Khorana score (KS) has not been well studied in East Asian cancer patients, who have different genetic backgrounds for inherited thrombophilia, body metabolism, and cancer epidemiology. METHODS: By using the Common Data Model, we retrospectively collected deidentified data from 11,71...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240689/ https://www.ncbi.nlm.nih.gov/pubmed/37271814 http://dx.doi.org/10.1186/s12959-023-00505-3 |
_version_ | 1785053827576102912 |
---|---|
author | Ha, Hyerim Ko, Yeh-Hee Kim, Kwangsoo Hong, Junshik Lee, Gyeong-Won Jeong, Seong Hyun Bang, Soo-Mee Yoon, Sung-Soo |
author_facet | Ha, Hyerim Ko, Yeh-Hee Kim, Kwangsoo Hong, Junshik Lee, Gyeong-Won Jeong, Seong Hyun Bang, Soo-Mee Yoon, Sung-Soo |
author_sort | Ha, Hyerim |
collection | PubMed |
description | BACKGROUND: The Khorana score (KS) has not been well studied in East Asian cancer patients, who have different genetic backgrounds for inherited thrombophilia, body metabolism, and cancer epidemiology. METHODS: By using the Common Data Model, we retrospectively collected deidentified data from 11,714 consecutive newly diagnosed cancer patients who underwent first-line chemotherapy from December 2015 to December 2021 at a single institution in Korea, and we applied the KS for cancer-associated thrombosis (CAT) prediction. Age at diagnosis, sex, and use of highly thrombogenic chemotherapeutics were additionally investigated as potential risk factors for CAT development. RESULTS: By 6 months after chemotherapy initiation, 207 patients (1.77%) experienced CAT. Only 0.4% had a body mass index (BMI) ≥ 35 kg/m(2) and changing the cutoff to 25 kg/m(2) improved the prediction of CAT. Age ≥ 65 years and the use of highly thrombogenic chemotherapeutics were independently associated with CAT development. KS values of 1 ~ 2 and ≥ 3 accounted for 52.3% and 7.6% of all patients, respectively, and the incidence of CAT in these groups was 2.16% and 4.16%, respectively, suggesting a lower incidence of CAT in the study population than in Westerners. The KS component regarding the site of cancer showed a good association with CAT development but needed some improvement. CONCLUSION: The KS was partially validated to predict CAT in Korean cancer patients undergoing modern chemotherapy. Modifying the BMI cutoff, adding other risk variables, and refining the use of cancer-site data for CAT risk prediction may improve the performance of the KS for CAT prediction in East Asian patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00505-3. |
format | Online Article Text |
id | pubmed-10240689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102406892023-06-06 Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy Ha, Hyerim Ko, Yeh-Hee Kim, Kwangsoo Hong, Junshik Lee, Gyeong-Won Jeong, Seong Hyun Bang, Soo-Mee Yoon, Sung-Soo Thromb J Research BACKGROUND: The Khorana score (KS) has not been well studied in East Asian cancer patients, who have different genetic backgrounds for inherited thrombophilia, body metabolism, and cancer epidemiology. METHODS: By using the Common Data Model, we retrospectively collected deidentified data from 11,714 consecutive newly diagnosed cancer patients who underwent first-line chemotherapy from December 2015 to December 2021 at a single institution in Korea, and we applied the KS for cancer-associated thrombosis (CAT) prediction. Age at diagnosis, sex, and use of highly thrombogenic chemotherapeutics were additionally investigated as potential risk factors for CAT development. RESULTS: By 6 months after chemotherapy initiation, 207 patients (1.77%) experienced CAT. Only 0.4% had a body mass index (BMI) ≥ 35 kg/m(2) and changing the cutoff to 25 kg/m(2) improved the prediction of CAT. Age ≥ 65 years and the use of highly thrombogenic chemotherapeutics were independently associated with CAT development. KS values of 1 ~ 2 and ≥ 3 accounted for 52.3% and 7.6% of all patients, respectively, and the incidence of CAT in these groups was 2.16% and 4.16%, respectively, suggesting a lower incidence of CAT in the study population than in Westerners. The KS component regarding the site of cancer showed a good association with CAT development but needed some improvement. CONCLUSION: The KS was partially validated to predict CAT in Korean cancer patients undergoing modern chemotherapy. Modifying the BMI cutoff, adding other risk variables, and refining the use of cancer-site data for CAT risk prediction may improve the performance of the KS for CAT prediction in East Asian patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-023-00505-3. BioMed Central 2023-06-05 /pmc/articles/PMC10240689/ /pubmed/37271814 http://dx.doi.org/10.1186/s12959-023-00505-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ha, Hyerim Ko, Yeh-Hee Kim, Kwangsoo Hong, Junshik Lee, Gyeong-Won Jeong, Seong Hyun Bang, Soo-Mee Yoon, Sung-Soo Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title_full | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title_fullStr | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title_full_unstemmed | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title_short | Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy |
title_sort | application of the khorana score for cancer-associated thrombosis prediction in patients of east asian ethnicity undergoing ambulatory chemotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240689/ https://www.ncbi.nlm.nih.gov/pubmed/37271814 http://dx.doi.org/10.1186/s12959-023-00505-3 |
work_keys_str_mv | AT hahyerim applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT koyehhee applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT kimkwangsoo applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT hongjunshik applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT leegyeongwon applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT jeongseonghyun applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT bangsoomee applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy AT yoonsungsoo applicationofthekhoranascoreforcancerassociatedthrombosispredictioninpatientsofeastasianethnicityundergoingambulatorychemotherapy |